The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
Open accessAbstract
BACKGROUNDOsimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKIsensitizing and EGFR T790M resistance mutations.A phase 3 trial compared firstline osimertinib with other EGFR-TKIs in patients with EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC).The trial showed longer progressionfree survival with osimertinib than with the comparator EGFR-TKIs (hazard ratio for disease progression or death, 0.46).Data from the final analysis of overall survival have not been reported. METHODSIn this trial, we randomly assigned 556 patients with previously untreated advanced NSCLC with an EGFR mutation (exon 19 deletion or L858R allele) in a 1:1 ratio to receive either osimertinib (80 mg once daily) or one of two other EGFR-TKIs (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily, with patients receiving these drugs combined in a single comparator group).Overall survival was a secondary end point. RESULTSThe median overall survival was 38.6 months (95% confidence interval [CI], 34.5 to 41.8) in the osimertinib group and 31.8 months (95% CI, 26.6 to 36.0) in the comparator group (hazard ratio for death, 0.80; 95.05% CI, 0.64 to 1.00; P = 0.046).At 3 years, 79 of 279 patients (28%) in the osimertinib group and 26 of 277 (9%) in the comparator group were continuing to receive a trial regimen; the median exposure was 20.7 months and 11.5 months, respectively.Adverse events of grade 3 or higher were reported in 42% of the patients in the osimertinib group and in 47% of those in the comparator group. CONCLUSIONSAmong patients with previously untreated advanced NSCLC with an EGFR mutation, those who received osimertinib had longer overall survival than those who received a comparator EGFR-TKI.The safety profile for osimertinib was similar to that of the comparator EGFR-TKIs, despite a longer duration of exposure in the osimertinib group.(Funded by AstraZeneca; FLAURA ClinicalTrials.govnumber, NCT02296125.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The second- and third-generation TKIs have shown significantly longer PFS compared with first-generation TKIs, and the third-generation TKI, osimertinib, has shown superior OS compared with first-generation TKIs.”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [49]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“in the recent FLAURA head-to-head trial, first-line treatment with osimertinib led to superior PFS and OS compared with a first-generation TKI (gefitinib or erlotinib).”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [49]
In the citing paper
“Patients with classical EGFR mutations (L858R or exon 19 deletions (Ex19del)) show marked improvements in clinical outcomes when treated with first-, second- or third-generation tyrosine kinase inhibitors (TKIs)4–6,11.”
From Structure-based classification predicts drug response in EGFR-mutant NSCLC (2021) · cites this paper as [11]
In the citing paper
“In the first line setting, EGFR-tyrosine kinase inhibitors have shown efficacy, particularly with osimertinib. 21 22”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citationOsimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Self-citationRosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Self-citationOsimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
Self-citationPlanchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274
Self-citationCross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246
Yang, J. C.-H., Wu, Y.-L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., Zhou, C., Hu, C.-P., O'Byrne, K., Feng, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71173-8 · Cited by 1,574
Self-citationMiller, V. A., Hirsh, V., Cadranel, J., Chen, Y.-M., Park, K., Kim, S.-W., Zhou, C., Su, W.-C., Wang, M., Sun, Y., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70087-6 · Cited by 961
Self-citationAzzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D. H., Laskin, J. L., Masters, G., Milton, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.5622 · Cited by 915
Reungwetwattana, T., Nakagawa, K., Cho, B. C., Cobo, M., Cho, E. K., Bertolini, A., Bohnet, S., Zhou, C., Lee, K. H., Nogami, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.3118 · Cited by 811
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Thai, A. A., Solomon, B., Sequist, L. V. D., Gainor, J. F., & Heist, R. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00312-3 · Cited by 2,753
Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer
Wu, Y.-L. L. C., Tsuboi, M., He, J., John, T., Grohé, C., Majem, M., Goldman, J. W., Лактионов, К. К., Kim, S., Kato, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2027071 · Cited by 1,849
Self-citationNon–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0025 · Cited by 1,430
Mosele, F., Remón, J., Mateo, J., Westphalen, C. B., Barlési, F., Lolkema, M. P., Normanno, N., Scarpa, A., Robson, M. E., Meric‐Bernstam, F., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.014 · Cited by 1,235
Toward personalized treatment approaches for non-small-cell lung cancer
Wang, M., Herbst, R. S., & Boshoff, C. (2021) · Nature Medicine · doi:10.1038/s41591-021-01450-2 · Cited by 1,127
Kinase drug discovery 20 years after imatinib: progress and future directions
Cohen, P., Cross, D. A. E., & Janne, P. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00195-4 · Cited by 1,092
Hendriks, L. E. L., Kerr, K. M., Menis, J., Mok, T. S. K., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.009 · Cited by 926
Self-citationTargeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
Tan, A. C., & Tan, D. S. W. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01626 · Cited by 810
Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC
Planchard, D., Janne, P. A., Cheng, Y., Yang, J. C., Yanagitani, N., Kim, S., Sugawara, S., Yu, Y., Fan, Y., Geater, S. L., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306434 · Cited by 772
Self-citationOverall Survival with Osimertinib in Resected EGFR -Mutated NSCLC
Tsuboi, M., Herbst, R. S., John, T., Kato, T., Majem, M., Grohé, C., Wang, J., Goldman, J. W., Lü, S., Su, W., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304594 · Cited by 691
Self-citationNon‐small cell lung cancer in China
Chen, P., Liu, Y., Wen, Y., & Zhou, C. (2022) · 癌症：英文版 · doi:10.1002/cac2.12359 · Cited by 682
Self-citationHendriks, L. E. L., Remón, J., Finn, C. F., Garassino, M. C., Heymach, J. V., Kerr, K. M., Tan, D. S. W., Veronesi, G., & Reck, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00551-9 · Cited by 690
Park, K., Haura, E. B., Leighl, N. B., Mitchell, P., Shu, C. A., Girard, N., Viteri, S., Han, J., Kim, S., Lee, C. K., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00662 · Cited by 681
Self-citationUpdate 2020: Management of Non-Small Cell Lung Cancer
Alexander, M., Kim, S. Y., & Cheng, H. (2020) · Lung · doi:10.1007/s00408-020-00407-5 · Cited by 663
Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma
Goyal, L., Meric‐Bernstam, F., Hollebecque, A., Valle, J. W., Morizane, C., Karasic, T. B., Abrams, T. A., Furuse, J., Kelley, R. K., Cassier, P. A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2206834 · Cited by 644
Rhun, É. L., Gückenberger, M., Smits, M., Dummer, R., Bachelot, T., Sahm, F., Galldiks, N., de Azambuja, E., Berghoff, A. S., Métellus, P., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.07.016 · Cited by 607
Overcoming therapy resistance in EGFR-mutant lung cancer
Passaro, A., Jänne, P. A., Mok, T., & Peters, S. (2021) · Nature Cancer · doi:10.1038/s43018-021-00195-8 · Cited by 565
Имянитов, Е. Н., Iyevleva, A. G., & Levchenko, E. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103194 · Cited by 538
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
Cooper, A. J., Sequist, L. V. D., & Lin, J. J. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00639-9 · Cited by 537
Global burden and trends of lung cancer incidence and mortality
Li, C., Lei, S., Ding, L., Xu, Y., Wu, X., Wang, H., Zhang, Z., Gao, T., Zhang, Y., & Li, L. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002529 · Cited by 539
Structure-based classification predicts drug response in EGFR-mutant NSCLC
Robichaux, J. P., Le, X., Vijayan, R. S. K., Hicks, J. K., Heeke, S., Elamin, Y. Y., Lin, H. Y., Udagawa, H., Skoulidis, F., Tran, H., et al. (2021) · Nature · doi:10.1038/s41586-021-03898-1 · Cited by 490
Self-citationTargeting cytokine and chemokine signaling pathways for cancer therapy
Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 528
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
Huang, L., Jiang, S., & Shi, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00977-0 · Cited by 478
Hanna, N. H., Schneider, B. J., Temin, S., Baker, S., Brahmer, J. R., Ellis, P. M., Gaspar, L. E., Haddad, R. Y., Hesketh, P. J., Jain, D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03022 · Cited by 467
Passaro, A., Wang, J., Wang, Y., Lee, S.-H., Melosky, B. L., Shih, J., Wang, J., Azuma, K., Juan, Ó., Cobo, M., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.117 · Cited by 460
Self-citationMosele, M. F., Westphalen, C. B., Stenzinger, A., Barlési, F., Bayle, A., Bièche, I., Bonastre, J., Castro, E., Dienstmann, R., Krämer, A., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.04.005 · Cited by 468
Fu, K., Xie, F., Wang, F., & Fu, L. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01391-4 · Cited by 432
Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer
Suehnholz, S. P., Nissan, M. H., Zhang, H., Kundra, R., Nandakumar, S., Lu, C., Carrero, S., Dhaneshwar, A., Fernandez, N. C., Xu, B. W., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0467 · Cited by 428
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
Zhou, C., Tang, K., Cho, B. C., Liu, B., Paz-Ares, L. G., Cheng, S. Y.-S., Kitazono, S., Thiagarajan, M., Goldman, J. W., Sabari, J. K., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306441 · Cited by 415
Self-citationAdvances in systemic therapy for non-small cell lung cancer
Miller, M., & Hanna, N. H. (2021) · BMJ · doi:10.1136/bmj.n2363 · Cited by 396
Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC
Le, X., Nilsson, M. B., Goldman, J. W., Reck, M., Nakagawa, K., Kato, T., Ares, L. P., Frimodt‐Moller, B., Wolff, K., Visseren‐Grul, C., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.10.006 · Cited by 357
Emerging therapeutic agents for advanced non-small cell lung cancer
Chen, R., Manochakian, R., James, L. E., Azzouqa, A., Shi, H., Zhang, Y., Zhao, Y., Zhou, K., & Lou, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00881-7 · Cited by 347
Oncogenic driver mutations in non-small cell lung cancer: Past, present and future
Chevallier, M., Borgeaud, M., Addeo, A., & Friedlaender, A. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i4.217 · Cited by 339
He, J., Huang, Z., Han, L., Gong, Y. Q., & Xie, C. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5270 · Cited by 339
Overcoming resistance to tumor-targeted and immune-targeted therapies
Aldea, M., Andre, F., Marabelle, A., Dogan, S., Barlesi, F., & Soria, J.-C. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1638 · Cited by 311
Self-citationLü, S., Dong, X., Jian, H., Chen, J., Chen, G., Sun, Y., Ji, Y., Wang, Z., Shi, J., Lu, J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02641 · Cited by 311
ctDNA as a cancer biomarker: A broad overview
Pessoa, L. S., Heringer, M., & Ferrer, V. P. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103109 · Cited by 311
Hanna, N. H., Robinson, A. G., Temin, S., Baker, S., Brahmer, J. R., Ellis, P. M., Gaspar, L. E., Haddad, R. Y., Hesketh, P. J., Jain, D., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03570 · Cited by 307
Janne, P. A., Baik, C., Su, W.-C., Johnson, M. L., Hayashi, H., Nishio, M., Kim, D.-W., Koczywas, M., Gold, K. A., Steuer, C. E., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0715 · Cited by 302
ROS1-dependent cancers — biology, diagnostics and therapeutics
Drilon, A. E. D. C., Jenkins, C., Iyer, S. R., Schoenfeld, A. J., Keddy, C., & Davare, M. A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0408-9 · Cited by 304
Chmielecki, J., Gray, J. E., Cheng, Y., Ohe, Y., Imamura, F., Cho, B. C., Lin, M., Majem, M., Shah, R. N. H., Rukazenkov, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-35961-y · Cited by 298
Self-citationThe blood–tumour barrier in cancer biology and therapy
Steeg, P. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00529-6 · Cited by 309
Papadimitrakopoulou, V. A., Mok, T. S. K., Han, J., Ahn, M., Delmonte, A., Ramalingam, S. S., Kim, S., Shepherd, F. A., Laskin, J. J., He, Y., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2100 · Cited by 282
Self-citationEmerging role of tumor cell plasticity in modifying therapeutic response
Qin, S., Jiang, J., Lü, Y., Nice, E. C., Huang, C., Zhang, J., & He, W. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00313-5 · Cited by 282
Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology
Mithoowani, H., & Febbraro, M. (2022) · Current Oncology · doi:10.3390/curroncol29030150 · Cited by 281
Wu, Y.-L. L. C., Cheng, Y., Zhou, J., Lü, S., Zhang, Y., Zhao, J., Kim, D., Soo, R. A., Kim, S., Pan, H., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30154-5 · Cited by 257
Self-citationRodak, O., Peris‐Díaz, M. D., Olbromski, M., Podhorska‐Okołów, M., & Dzięgiel, P. (2021) · Cancers · doi:10.3390/cancers13184705 · Cited by 250
Zhou, Q. H., Xu, C., Cheng, Y., Liu, Y., Chen, G., Cui, J., Yang, N., Song, Y., Li, X., Lü, S., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.07.005 · Cited by 236
Self-citationWaarts, M. R., Stonestrom, A. J., Park, Y. C., & Levine, R. L. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154943 · Cited by 249
Shi, Y., Chen, G., Wang, X., Liu, Y., Wu, L., Hao, Y., Liu, C., Zhu, S., Zhang, X., Li, Y., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00168-0 · Cited by 236
Self-citationNagasaka, M., Zhu, V. W., Lim, S. M., Greco, M., Wu, F., & Ou, S.-H. I. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.028 · Cited by 219
Passaro, A., Mok, T. S. K., Peters, S., Popat, S., Ahn, M., & de Marinis, F. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.12.002 · Cited by 219
Aizer, A. A., Lamba, N., Ahluwalia, M. S., Aldape, K., Boire, A. A., Brastianos, P. K., Brown, P. D., Camidge, D. R., Chiang, V., Davies, M. A., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac118 · Cited by 217
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
HARMONi-A Study Investigators, Fang, W., Zhao, Y., Luo, Y., Yang, R., Huang, Y., He, Z., Zhao, H., Li, M., Li, K., et al. (2024) · JAMA · doi:10.1001/jama.2024.10613 · Cited by 218
Self-citationSquamous cell lung cancer: Current landscape and future therapeutic options
Lau, S. C. M., Pan, Y., Velcheti, V., & Wong, K. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.09.018 · Cited by 215
Update 2025: Management of Non‑Small-Cell Lung Cancer
Jeon, H., Wang, S., Song, J., Gill, H., & Cheng, H. (2025) · Lung · doi:10.1007/s00408-025-00801-x · Cited by 229
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
Passaro, A., Leighl, N. B., Blackhall, F. H., Popat, S., Kerr, K. M., Ahn, M., Arcila, M. E., Arrieta, O. G., Planchard, D., de Marinis, F., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.02.003 · Cited by 209
Self-citationThe changing treatment landscape of EGFR-mutant non-small-cell lung cancer
Zhou, F., Guo, H., Xia, Y., Le, X., Tan, D. S. W., Ramalingam, S. S., & Zhou, C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00971-2 · Cited by 230
Self-citationEGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
Friedlaender, A., Subbiah, V., Russo, A., Banna, G. L., Malapelle, U., Rolfo, C. D., & Addeo, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00558-1 · Cited by 206
Small molecule inhibitors targeting the cancers
Liu, G., Chen, T., Zhang, X., Ma, X., & Shi, H. (2022) · MedComm · doi:10.1002/mco2.181 · Cited by 212
Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer
Jee, J., Lebow, E. S., Yeh, R., Das, J. P., Namakydoust, A., Paik, P. K., Chaft, J. E., Jayakumaran, G., Brannon, A. R., Benayed, R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02047-z · Cited by 201
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Eno, M. S., Brubaker, J. D., Campbell, J. E., Savi, C. D., Guzi, T. J., Williams, B. D., Wilson, D. P., Wilson, K. J., Brooijmans, N., Kim, J., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00704 · Cited by 198
Smeltzer, M. P., Wynes, M. W., Lantuéjoul, S., Soo, R. A., Ramalingam, S. S., Varella‐Garcia, M., Taylor, M. M., Richeimer, K., Wood, K., Howell, K. E., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.05.002 · Cited by 196
Self-citationMechanisms of osimertinib resistance and emerging treatment options
Schmid, S., Li, J. J. N., & Leighl, N. B. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.07.014 · Cited by 193
Tsuboi, M., Weder, W., Escriu, C., Blakely, C. M., He, J., Đačić, S., Yatabe, Y., Zeng, L., Walding, A., & Chaft, J. E. (2021) · Future Oncology · doi:10.2217/fon-2021-0549 · Cited by 194
Park, S., Kim, T. M., Han, J., Lee, G., Shim, B. Y., Lee, Y., Kim, S., Kim, I. H., Lee, S., Kim, Y. J., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01891 · Cited by 192
Self-citationEmerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer
Cabanos, H. F., & Hata, A. N. (2021) · Cancers · doi:10.3390/cancers13112666 · Cited by 189
Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review
Piper‐Vallillo, A. J., Sequist, L. V. D., & Piotrowska, Z. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03123 · Cited by 190
Park, S., Lee, M.-H., Seong, M., Kim, S. T., Kang, J. H., Cho, B. C., Lee, K. H., Cho, E. K., Sun, J., Lee, S.-H., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.017 · Cited by 184
Self-citationManagement of brain metastases according to molecular subtypes
Soffietti, R., Ahluwalia, M. S., Lin, N., & Rudà, R. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0391-x · Cited by 175
Emerging strategies to overcome resistance to third-generation EGFR inhibitors
Shi, K., Wang, G., Pei, J., Zhang, J., Wang, J., Ouyang, L., Wang, Y., & Li, W. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01311-6 · Cited by 174
Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors
Du, X., Yang, B., An, Q., Assaraf, Y. G., Cao, X., & Xia, J. (2021) · The Innovation · doi:10.1016/j.xinn.2021.100103 · Cited by 171
Cheng, Y., He, Y., Li, W., Zhang, H., Zhou, Q. H., Wang, B., Liu, C., Walding, A., Saggese, M., Huang, X., et al. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00794-6 · Cited by 172
Self-citationConcurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma
Vokes, N. I., Chambers, E. S., Nguyen, T. T., Coolidge, A., Lydon, C., Le, X., Sholl, L. M., Heymach, J. V., Nishino, M., Allen, E. M. V., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.02.011 · Cited by 170
Padinharayil, H., Varghese, J., John, M. C., Rajanikant, G. K., Wilson, C. M., Al-Yozbaki, M., Renu, K., Dewanjee, S., Sanyal, R., Dey, A., et al. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.07.023 · Cited by 172
Tanaka, K., Yu, H. A., Yang, S., Han, S., Selçuklu, S. D., Kim, K., Ramani, S., Ganesan, Y. T., Moyer, A. F., Sinha, S., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.07.006 · Cited by 169
Ahn, M., Chiu, C., Cheng, Y., Han, J., Goldberg, S. B., Greystoke, A., Crawford, J., Zhao, Y., Huang, X., Johnson, M. G., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.12.113 · Cited by 163
Self-citationAt the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
Otano, I., Ucero, A. C., Zugazagoitia, J., & Paz-Ares, L. G. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00718-x · Cited by 167
Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors
Cobain, E. F., Wu, Y., Vats, P., Chugh, R. K., Worden, F. P., Smith, D. C., Schuetze, S. M., Zalupski, M. M., Sahai, V., Alva, A. S., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.7987 · Cited by 159
Management of locally advanced non‐small cell lung cancer: State of the art and future directions
Miao, D., Zhao, J., Han, Y., Zhou, J., Li, X., Zhang, T., Li, W., & Xia, Y. (2023) · 癌症：英文版 · doi:10.1002/cac2.12505 · Cited by 165
Johnson, M. L., Garassino, M. C., Mok, T. S. K., & Mitsudomi, T. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.05.011 · Cited by 159
Wu, Y.-L. L. C., John, T., Grohé, C., Majem, M., Goldman, J. W., Kim, S., Kato, T., Лактионов, К. К., Vũ, H. V., Wang, Z., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.10.014 · Cited by 154
Self-citationCho, B. C., Ahn, M., Kang, J. H., Soo, R. A., Reungwetwattana, T., Yang, J. C., Çiçin, İ., Kim, D., Wu, Y.-L. L. C., Lü, S., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00515 · Cited by 155
Self-citationRecent advances in therapeutic strategies for non-small cell lung cancer
Su, P., Furuya, N., Asrar, A., Rolfo, C. D., Li, Z., Carbone, D. P., & He, K. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01679-1 · Cited by 164
Lü, S., Wang, Q., Zhang, G., Dong, X., Yang, C., Song, Y., Chang, G., Lü, Y., Pan, H., Chiu, C., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.10.024 · Cited by 149
Self-citationOverall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC
Yang, J. C., Lu, S., Hayashi, H., Felip, E., Spira, A. I., Girard, N., Kim, Y. J., Lee, S.-H., Ostapenko, Y., Danchaivijitr, P., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2503001 · Cited by 149
Self-citationTada, H., Mitsudomi, T., Misumi, T., Sugio, K., Tsuboi, M., Okamoto, I., Iwamoto, Y., Sakakura, N., Sugawara, S., Atagi, S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01729 · Cited by 147
Janne, P. A., Planchard, D., Kobayashi, K., Cheng, Y., Lee, C. K., Valdiviezo, N., Лактионов, К. К., Yang, T., Yu, Y., Kato, T., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.02219 · Cited by 147
Self-citationOncogenic alterations in advanced NSCLC: a molecular super-highway
Friedlaender, A., Pérol, M., Banna, G. L., Parikh, K., & Addeo, A. (2024) · Biomarker Research · doi:10.1186/s40364-024-00566-0 · Cited by 150
Lamberti, G., Andrini, E., Sisi, M., Rizzo, A., Parisi, C., Federico, A. D., Gelsomino, F., & Ardizzoni, A. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103119 · Cited by 147
Zhang, K.-R., Zhang, Y.-F., Lei, H.-M., Tang, Y., Ma, C., Lv, Q.-M., Wang, S.-Y., Lu, L., Shen, Y. H., Chen, H., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abg6428 · Cited by 149
Kawashima, Y., Fukuhara, T., Saito, H., Furuya, N., Watanabe, K., Sugawara, S., Iwasawa, S., Tsunezuka, Y., Yamaguchi, O., Okada, M., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00166-1 · Cited by 140
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
Janne, P. A., Planchard, D., Kobayashi, K., Yang, J. C., Liu, Y. L., Valdiviezo, N., Kim, T. M., Jiang, L., Kagamu, H., Yanagitani, N., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2510308 · Cited by 133
Self-citationSands, J., Ahn, M.-J., Lisberg, A., Cho, B. C., Blumenschein, G., Shum, E., Pons Tostivint, E., Goto, Y., Yoh, K., Heist, R., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-01349 · Cited by 130
“5,6 First-line and second-line treatment approaches for NSCLC with actionable genomic alterations consist mostly of targeted treatment with tyrosine kinase inhibitors (TKIs).”
InfluentialSelf-citationSperduto, P. W., De, B. S., Li, J., Carpenter, D. J., Kirkpatrick, J. P., Milligan, M., Shih, H. A., Kütük, T., Kotecha, R. R., Higaki, H., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.03.020 · Cited by 134
EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins
Remón, J., Hendriks, L. E. L., Cardona, A. F., & Besse, B. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102105 · Cited by 130
Cheng, Y., Zhang, T., & Xu, Q. (2021) · MedComm · doi:10.1002/mco2.105 · Cited by 131
Self-citationNaidoo, J., Antonia, S. J., Wu, Y.-L. L. C., Cho, B. C., Thiyagarajah, P., Mann, H., Newton, M., & Finn, C. F. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.02.009 · Cited by 126
Self-citationGillespie, C. S., Mustafa, M. A., Richardson, G. E., Alam, A. M., Lee, K. S., Hughes, D. M., Escriu, C., & Zakaria, R. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.06.017 · Cited by 122
Self-citation
Metadata
- Authors
- Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., Zhou, C., Reungwetwattana, T., Cheng, Y., Chewaskulyong, B., Shah, R., Cobo, M., Lee, K. H., Cheema, P., Tiseo, M., John, T., Lin, M.-C., Imamura, F., Kurata, T., Todd, A., Hodge, R., Saggese, M., Rukazenkov, Y., & Soria, J.-C.
- Affiliations
- Université Paris-Sud (FR)
- From Winship Cancer Institute, Emory University School of Medicine, Atlanta (S.S.R.); the Respiratory Oncology Unit, Department of Respiratory Medicine, University Hospital KU Leuven, Leuven, Belgium (J.V.); the Thoracic Unit, Department of Medical Oncology, Institut Gustave Roussy, Villejuif (D.P., J.-C.S.), and University Paris Sud, Orsay (J.-C.S.) — both in France; the Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul...
- ORCID
- Ramalingam, Suresh S.
- Vansteenkiste, Johan
- Planchard, David
- Cho, Byoung Chul
- Gray, Jhanelle E.
- Ohe, Yuichiro
- Zhou, Caicun
- Reungwetwattana, Thanyanan
- Cheng, Ying
- Shah, Riyaz
- Cobo, Manuel
- Lee, Ki Hyeong
- Cheema, Parneet
- Tiseo, Marcello
- John, Thomas
- Lin, Meng-Chih
- Imamura, Fumio
- Kurata, Takayasu
- Todd, Alexander
- Hodge, Rachel
- Soria, Jean-Charles
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-01-02
- Volume
- 382
- Issue
- 1
- Pages
- 41-50
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2990041408
- Cited by
- 2,914
- References
- 27
- Citations by year
- 2026: 354 · 2025: 462 · 2024: 487 · 2023: 411 · 2022: 480 · 2021: 434 · 2020: 284
- FWCI
- 222.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Lirias (submittedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- AstraZeneca (N/A)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- osimertinib, EGFR-mutant non-small cell lung cancer, EGFR tyrosine kinase inhibitors, gefitinib, erlotinib, first-line therapy, overall survival, exon 19 deletion, L858R mutation, T790M resistance, progression-free survival, adverse events, treatment duration
- MeSH terms
- Erlotinib Hydrochloride, Gefitinib, Acrylamides, Aged, Aniline Compounds, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Double-Blind Method, Female, Humans, Indoles, Lung Neoplasms, Male, Middle Aged, Mutation, Pyrimidines, Proportional Hazards Models, Protein Kinase Inhibitors, Kaplan-Meier Estimate, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
